Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

NCT06021678 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

415

Enrollment

INDUSTRY

Sponsor class

Conditions

CD20-positive Non-Hodgkin Lymphoma

Interventions

DRUG: EX103 injection

Sponsor

Guangzhou Excelmab Inc.